Journal article icon

Journal article

An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib

Abstract:

Background Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the approved 400 mg twice-daily dose; a tablet formulation was developed to reduce pill burden. This clinical trial evaluated the optimal dose and administration schedule of the tablet formulation. Patients and Methods Two stages of sequentially enrolled cohorts: stage 1, pharmacokinetic properties of tablet and capsule formulations were comp...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1007/s11523-016-0435-8

Authors


Expand authors...
Publisher:
Springer International Publishing Switzerland Publisher's website
Journal:
Targeted Oncology Journal website
Volume:
11
Issue:
3
Pages:
401–415
Publication date:
2016-05-12
Acceptance date:
2015-12-17
DOI:
EISSN:
1776-260X
ISSN:
1776-2596
URN:
uuid:16e8a394-8fd8-4041-bb2e-ef37219c154e
Source identifiers:
622401
Local pid:
pubs:622401
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP